Peginterferon lambda-1a is a recombinant protein commercialized by Eiger BioPharmaceuticals, with a leading Phase III program in Hepatitis D. According to Globaldata, it is involved in 26 clinical trials, of which 17 were completed, 3 are ongoing, 3 are planned, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Peginterferon lambda-1a’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Peginterferon lambda-1a is expected to reach an annual total of $133 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Peginterferon lambda-1a Overview

Peginterferon lambda-1a is under development for the treatment of hepatitis delta virus infections and coronavirus disease 2019 (COVID-19). The drug candidate is administered by subcutaneous route. PEG-IFN lambda (BMS-914143) is a type III interferon. Interferons are a family of pleiotropic cytokines with antiviral, anti-proliferative and immuno-modulatory properties. The interferons targets membrane receptor (IFNAR). It was also under development for the treatment of hepatitis B and hepatitis C viral infection.

Eiger BioPharmaceuticals Overview

Eiger BioPharmaceuticals (Eiger), formerly known as Celladon, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of novel drugs for the treatment of orphan diseases. The company provides products such as lonafarnib and lambda which are used for the treatment of hepatitis delta virus infection; exendin 9-39 post-bariatric hypoglycemia; ubenimex for lymphedema and pulmonary arterial hypertension. It also offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. The company also offers post-bariatric hypoglycemia prevention services. Eiger is headquartered in Palo Alto, California, the US.

The company reported revenues of (US Dollars) US$12.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$76.9 million in FY2021, compared to an operating loss of US$62.2 million in FY2020. The net loss of the company was US$33.9 million in FY2021, compared to a net loss of US$65.1 million in FY2020. The company reported revenues of US$4 million for the third quarter ended September 2022, a decrease of 1.6% over the previous quarter.

For a complete picture of Peginterferon lambda-1a’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.